Physician profile
Jimmy Lin
NPI 1952328585
$8,358.44
in general payments reported to CMS, 2019-2025
31 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $1,287 · 2021: $1,323 · 2022: $1,079 · 2023: $1,004 · 2024: $953 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,213.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,162.98 | 2019-2025 | |
| Amgen INC. | $931.10 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $805.34 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $640.59 | 2019-2023 | |
| Ibsa Pharma INC. | $598.45 | 2021-2025 | Tirosint, Licart, Tirosint |
| Janssen Pharmaceuticals, INC | $517.32 | 2019-2022 | |
| Pfizer INC. | $467.25 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $459.19 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $434.57 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.92 | 2020-2023 | Jardiance |
| Lilly USA, LLC | $341.20 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $303.34 | 2019-2025 | |
| Eisai INC. | $265.63 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $208.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $155.87 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $103.88 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $103.63 | 2019-2024 | Arexvy |
| Esperion Therapeutics, INC. | $85.71 | 2020-2024 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $60.13 | 2019 | |
| Radius Health, INC. | $49.47 | 2020 | |
| Sanofi Pasteur INC. | $48.82 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $48.67 | 2025 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $43.39 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $38.47 | 2022 | |
| Phathom Pharmaceuticals, INC. | $30.04 | 2025 | Voquezna |
| Allergan, INC. | $23.03 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.06 | 2022 | |
| Medtronic, INC. | $19.07 | 2025 | Venaseal |
| Takeda Pharmaceuticals U.S.A., INC. | $18.82 | 2023 | Trintellix |
| Genentech USA, INC. | $16.91 | 2020 | |
| Acorda Therapeutics, INC | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.